GlaxoSmithKline PLC ADR
GSK · NYSE58.26
58.26
USD-0.05-0.08%Data
Ticker
Titolo
Fonte
Key deals this week: Clorox, Spirit Airlines, GSK, PayPal, and more
Seeking Alpha
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
MarketWatch
GSK to buy Rapt Therapeutics in deal valued at $2.2B
SeekingAlpha
GSK turns to insider to be next CEO — and the stock rallies
MarketWatch
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit - CNBC
CNBC
GSK shares break six-session winning streak
SeekingAlpha
GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B
SeekingAlpha
M&A Snapshot: GSK to acquire IDRx in $1.15B deal, expanding in GI cancer therapy
SeekingAlpha
GSK to buy Boston-based IDRx for $1.15 billion
SeekingAlpha
GSK is said to be nearing $1B deal to acquire U.S. biotech IDRx
SeekingAlpha
GSK cuts vaccine sales target on reduced demand
MarketWatch
GSK to acquire lupus drug candidate CMG1A46 for up to $850M
SeekingAlpha
GSK settles vast majority of Zantac claims for $2.2 billion
MarketWatch
GSK shares jump on win in Delaware court over ongoing Zantac battle
MarketWatch
Live news: GSK shares drop as US narrows recommended age range for RSV vaccines - Financial Times
Financial Times
GSK stock falls more at London open following RSV vaccination news
MarketWatch
GSK buys RNA therapeutics company for up to $50M
SeekingAlpha
GSK lifts long-term outlook following launch of blockbuster vaccine in 2023
MarketWatch
Sell AstraZeneca, says UBS, which upgrades European rivals including GSK
MarketWatch
GSK to buy asthma drug developer for up to $1.4 billion in pipeline push
MarketWatch
GSK to buy Aiolos Bio for up to $1.4B to expand respiratory portfolio
SeekingAlpha
GSK looking to boost pipeline with respiratory, auto-immune deals - report
SeekingAlpha
RSV vaccine from GSK shows potential to protect adults 50 to 59
CNBC
GSK signs shingles vaccine deal with China's Zhifei for around $3 bln - Reuters
Reuters
GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales
CNBC
GSK completes $2B acquisition of Bellus Health
SeekingAlpha
Movers & Shakers: Virgin Galactic shares tumble, while Trupanian and GSK climb and other stocks on the move
MarketWatch
Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says
CNBC
CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults over 60
CNBC
GSK says RSV vaccine for older adults provides protection over two seasons
CNBC
Pfizer and GSK to battle for share of new RSV vaccine market: Report - Business Standard
Business Standard
Dow Jones Newswires: GSK first quarter profit dips to £1.49 billion but beat analyst forecasts
MarketWatch
The markets are closed!🔔 Here were today's top stories!👇 ✧ March single-family housing starts +2.7%, permits +4.1% ✦ $GS -2% as consumer business weighs on results ✧ $LMT +3%, beats estimates as supply chain improves ✦ $BLU +100% on $GSK buyout https://t.co/V3QP4mFX16 https://t.co/zKidmrvRgu
Movers & Shakers: Bellus Health’s stock climbs on GSK deal, while Goldman Sachs is hurt by a revenue miss
MarketWatch
Bellus surges ~100% after GSK reaches deal to acquire cough drugmaker for ~$2B
SeekingAlpha
FAQ
Cosa stai aspettando?Inizia a fare profitto oggi
Strumenti
Mercati
Più
Risorse
Confronta
App mobile Profit
Scopri il mondo della finanza nel tuo taschino
©
2026
Tutti i diritti riservati